3SBio, Inc. · HKEX:1530
3SBio — FY2012 Earnings Presentation
31 slides from 3SBio's earnings presentation, Mar 18, 2013
Slide 1: Results Presentation Fourth Quarter and Full Year 2012
Results Presentation Fourth Quarter and Full Year 2012 March 18, 2013 Care for Life, Cherish Life, Create Life
Slide 2: Safe Harbor Statement
Safe Harbor Statement Cautionary Statement concerning Forward Looking Statements Certain statements in the disclosures of 3SBio, Inc. (the “Company” or “3SBio”) for the fourth quarter and fiscal year 2012 (“Disclosures”) that are not purely historical in nature may constitute “forward-looking statem
Slide 3: Fourth Quarter and Full Year 2012 Overview
3SBio Investor Presentation Fourth Quarter and Full Year 2012 Overview Care for Life, Cherish Life, Create Life
Slide 4: Providing World Class Care for China's Future
Providing World Class Care for China’s Future 3SBio Inc. is a leading, fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China. Therapeutic focus on oncology and nephrology. 6 marketed products a
Slide 5: Company Highlights – Fourth Quarter 2012
Company Highlights – Fourth Quarter 2012 Solid Revenue Growth Led by EPIAO and TPIAO Products Total revenues grew 17.2% year-on-year EPIAO and TPIAO net revenues increased 6.9% and 30.8%, respectively Iron Sucrose net revenues increased 26.3% year-on-year Net export revenues increased 40.6% year-on-
Slide 6: 2012 Objectives
2012 Objectives Increase net revenues by 15-25% (US$99 million – US$108 million) Explore the potential market in the renal care area to further strengthen our leadership position in the nephrology area Evaluate manufacturing options for small-molecule medicines Initiate Phase I trial of NuPIAO, our
Slide 7: Fourth Quarter 2012 Financial Highlights
3SBio Investor Presentation Fourth Quarter 2012 Financial Highlights Care for Life, Cherish Life, Create Life
Slide 8: Financial Summary – 2012 Fourth Quarter
Financial Summary –2012 Fourth Quarter Fourth Quarter 2012 For the three months For the three months For the three months ( expressed in thousands, except per ended December 31, ended December 31, 2012 ended December 31, 2012 YoY % Inc/dec ADS data) 2011 (unaudited) RMB (unaudited) RMB (unaudited) U
Slide 9: Financial Summary – Full Year 2012
Financial Summary – Full Year2012 Full Year 2012 For the full year ended For the full year ended For the full year ( expressed in thousands, except per December 31, 2011 December 31, 2012 ended December 31, 2012 YoY % Inc/dec ADS data) (unaudited) RMB (unaudited) RMB (unaudited) US$ Net revenues 541
Slide 10: Strong Cash Position
Strong Cash Position Balance Sheet As of Dec ember 31, 2011 As of December 31, 2012 As of December 31, 2012 (expressed in thousands) RMB (unaudited) RMB (unaudited) US$ Cash, cash equivalents 245,813 450,557 72,319 Time deposits 519,201 441,294 70,832 Total current assets 992,727 1,123,287 180,300 T
Slide 11: Operational and strategic highlights
3SBio Investor Presentation Operational and strategic highlights Care for Life, Cherish Life, Create Life
Slide 12: Key Revenue Drivers - EPIAO & TPIAO
Key Revenue Drivers - EPIAO & TPIAO Healthy End-Market Fundamentals Drive Growth EPIAO – sustainable growth year-over-year driven by oncology and dialysis market penetration and expansion TPIAO – rapid growth demonstrates physician acceptance of product Continued product growth highlights underlying
Slide 13: Increasingly diversified revenue mix
Increasingly diversified revenue mix 100% 90% 80% Others 70% InLeusin 60% Intefen 50% Export 40% 30% Iron Sucrose 20% TPIAO 10% EPIAO 0% 2007 2008 2009 2010 2011 2012 13 Care for Life, Cherish Life, Create Life
Slide 14: Consistent Growth: EPIAO & TPIAO
Consistent Growth: EPIAO & TPIAO 4Q2012 EPIAO Highlights 4Q2012 TPIAO Highlights RMB88.1 million (US$14.1 million) in sales for RMB50.8 million (US$8.1 million) in sales for 4Q2012: 6.9% increase over 4Q2011 4Q2012: 30.8% increase over 4Q2011 Remains leading revenue contributor : 53.7% Remains the s
Slide 15: Manufacturing & GMP
Manufacturing & GMP First and only company in China to meet both Chinese Pharmacopoeia and European Pharmacopoeia standards following SFDA approval of voluntary manufacturing specification upgrade in fourth quarter 2011 New test specifies and quantifies isoforms using capillary zone electrophoresis
Slide 16: Exports
Exports Export Sales (US$m) 7.0 7.0% 6.4 EPIAO is registered in 17 6.0 6.0% 6.0% countries and applications are in 5.0 4.4% 5.0% progress in a further 8 countries. 4.2% 3.8 4.4% 3.8 4.0 4.0% 3.8% TPIAO is registered in Philippines, 3.0 3.4% 3.0% 2.9% Dominica and Paraguay. 1.9 1.9 2.0 2.0% 1.2 INTEF
Slide 17: R&D Pipeline
R&D Pipeline Candidate Indication(s) Pre- Phase Phase Phase SFDA Clini 1 2 3 Filing Feraheme An in-licensed intravenous iron replacement treatment for iron deficiency anemia in CKD patients and in patients requiring hemodialysis. SFDA registration trial application pending. Voclosporin An in-license
Slide 18: Strategy and Value Driven Business Development Approach
Pursuing Business Development and M&A Opportunities to Complement Organic Growth Strategy and Value Driven Business Development Approach Focused Business Development and Licensing Therapeutics that complement our existing product portfolio and commercial expertise in Oncology, Nephrology and Autoimm
Slide 19: Focused Strategies to Drive Growth and Profitability in 2013
Focused Strategies to Drive Growth and Profitability in 2013 Maximize sales of our lead products Explore the potential market in EPIAO and TPIAO and other existing the renal care area to further products in the nephrology and strengthen our leadership oncology markets in China position in the nephro
Slide 20: EPO China Market Growth
EPO China Market Growth Chinese Total EPO Market in Volume and Sales (1999-2012) 1,200 25,000 Value (RMB) 1,000 Volume (Vials in thousands) 20,000 Volume (Vials) Value (RMB millions) 800 15,000 600 10,000 400 5,000 200 0 0 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 Source:
Slide 21: EPIAO - The Market Leader
EPIAO - The Market Leader EPIAO has consistently outperformed the competition with 41.2% market share by value and 25.4% by unit volume in 4Q2012 EPO Market Share (Volume) EPO Market Share (Value) 50% 35% 32.6% 31.9% 45.7% 44.0% 29.1% 42.3% 42.5% 42.8% 42.9% 29.6% 30.2% 45% 41.3% 41.3% 40.6% 41.1% 4
Slide 22: EPIAO – Accelerated Growth
EPIAO – Accelerated Growth Chinese EPO Market Volume and Value (1999-2012) 5.7 600 6.0 3SBio 483 3SBio 4.6 500 5.0 383 RMB (millions) 3.7 400 Vials (millions) 4.0 3.0 301 3.0 2.6 300 248 2.0 213 2.0 200 156 1.2 1.4 113 122 0.9 0.9 73 85 1.0 0.6 0.7 100 46 55 0.1 0.3 15 28 0.0 0 2002 2008 1999 2000 2
Slide 23: Product Portfolio
Product Portfolio PRODUCT INDICATON LAUNCH EPIAO® (rhEPO) Anemia associated with renal failure 1998 (益比奥®） Chemotherapy Peri-operative blood cell mobilization TPIAO® (rhTPO) (特 Chemotherapy-induced thrombocytopenia “CIT” 2006 比澳®) Immune thrombocytopenia (“ITP”) 2012 Iron Sucrose Iron deficiency 200
Slide 24: Senior Management
Senior Management Dr. Jing Lou, MD, PhD, MBA; Has been with 3SBio since 1995, and built 3SBio into the leading Chinese biopharmaceutical company. Has Chairman of the Board/CEO more than 10 years’ pharmaceutical industry experience. Post-doctoral training at NIH, Ph.D. from Fordham University in Mole
Slide 25: Partnerships
3SBio Investor Presentation Partnerships Care for Life, Cherish Life, Create Life
Slide 26: Cooperation with DaVita
Cooperation with DaVita On March 9, 2012, 3SBio announced that it entered into a framework joint venture agreement with DaVita Inc., a Fortune 500 company that operates over 1,800 dialysis clinics which treat over 140,000 patients in the US and internationally. The joint venture will provide renal c
Slide 27: Ascentage Pharma
Ascentage Pharma Equity investment plus China development and commercialization rights A recent spin-off of Ascenta (Shanghai) R&D Center, a wholly owned subsidiary of Ascenta Therapeutics, Inc. which was established in August 2005. The team has an established track record in late stage discovery, p
Slide 28: Isotechnika / voclosporin
Isotechnika / voclosporin 3SBio obtained the exclusive rights for Greater China, including Hong Kong and Taiwan, from Isotechnika to all transplant and autoimmune indications of voclosporin, a new generation calcineurin inhibitor . Investment in Isotechnika Pharma (TSX:ISA) through a US$4.5 million
Slide 29: Uricase-PEG 20
Uricase-PEG 20 Acquired worldwide rights excluding Taiwan of Uricase-PEG 20 (formerly pegsiticase) for all indications for a total consideration of US$6.25 million. Uricase-PEG 20 is a pegylated recombinant uricase derived from Candida utilis, modified by the attachment of multiple 20 kilodalton mol
Slide 30: Uricase-PEG US Phase Trial Results
Uricase-PEG 20 US Phase 1 Trial Results Single intravenous infusions of Pharmacokinetics Uricase-PEG 20 (pegsiticase) were 6.0 0.05 mg/kg safe, well-tolerated, and effective [Uricase] (mcg/mL) 0.10 mg/kg 5.0 0.20 mg/kg at lowering uric acid levels in this 0.30 mg/kg 4.0 0.40 mg/kg phase 1 study. 3.0
Slide 31: Investor Relations Contacts
3SBio Investor Presentation Investor Relations Contacts Bo Tan Tom Folinsbee Chief Financial Officer Director, Corporate Development 3SBio Inc. 3SBio Inc. Tel: + 86 24 2581-1820 Tel: + 852 8191-6991 ir@3SBio.com tomfolinsbee@3SBio.com Care for Life, Cherish Life, Create Life